Based on 784 businesses audited.
Medical Devices, Pharma & Biotech Reputation: IMFINZI (durvalumab) (imfinzi.com)
This is a high-substance, low-BS pharmaceutical site that prioritizes regulatory compliance and clinical specificity over marketing fluff. The low score reflects a site that backs almost every indication claim with specific treatment protocols and FDA-approved contexts. The minor points are deducted for technical schema absences and repetitive heading structures rather than deceptive content.
Medical Devices, Pharma & Biotech Reputation: IMFINZI (durvalumab) (imfinzi.com)
The website perfectly aligns with the Pharma and Biotech industry, focusing on FDA-approved immunotherapy indications and regulatory-mandated safety information. The content is heavily clinical, discussing specific cancer stages like LS-SCLC and treatment regimens such as FLOT and chemoradiation therapy (CRT).
“The score of 86 is driven primarily by minor technical gaps in Identity and Authority (missing schema) and structural repetition in Information Density. The core messaging and clinical claims are highly substantiated, resulting in near-zero scores for Semantic Drift and Commodity Fingerprint.”